Combination therapy for liver cancer that cannot be removed
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study looks back at patients who received a combination of donafenib (a targeted pill), immunotherapy (a medicine that helps your immune system fight cancer), and a liver-directed procedure (TACE or HAIC) as their first treatment for liver cancer that can't be surgically removed. The goal is to check how well this combination works and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of liver cancer (hepatocellular carcinoma) that cannot be removed with surgery.
- You must have started this specific combination treatment (donafenib, immunotherapy, and a liver procedure) between June 2021 and November 2024, and taken it for at least 1 month.
- You must not have received any prior systemic treatment (like pills or IV therapy that travels through the body) before starting this combination.
- Your liver function must be relatively good (Child-Pugh class A or B), and you should be well enough to do your daily activities (ECOG score 0–1).
- If you had liver surgery before, the surgery must have been complete (all cancer removed) and the cancer came back more than 2 years later.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This trial tests a new combination of two immunotherapy drugs plus a targeted therapy and a procedure called TACE (which blocks the blood supply to the tumor) for people with advanced liver cancer. It aims to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two treatments—a targeted pill (donafenib) and an immunotherapy drug (pucotenlimab)—along with a type of chemotherapy given directly to the liver through a catheter. The goal is to see if this combination can shrink or control liver cancer better than standard options.
This trial tests a drug called Donafenib (a targeted therapy) taken after surgery to see if it can prevent liver cancer from coming back in people at high risk of recurrence.
This study tests a combination of two drugs (anlotinib and benmelstobart) with a liver-directed chemotherapy procedure (HAIC) in people with liver cancer that cannot be removed surgically. The goal is to see if this combo shrinks tumors and is safe.
This study tests a new combination treatment for advanced liver cancer that has stopped responding to earlier therapy. It combines the targeted drug donafenib with immunotherapy and local treatments, which may help control the tumor better than the previous treatments.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.